Today: 21 May 2026
Bitcoin price breaks below $90,000 as global selloff hits crypto and traders eye the next floor
21 January 2026
2 mins read

Bitcoin price breaks below $90,000 as global selloff hits crypto and traders eye the next floor

Singapore, Jan 21, 2026, 20:08 SGT

  • Bitcoin dropped beneath $90,000, a threshold investors have eyed closely throughout this year
  • The decline followed a broader risk-off shift hitting both stocks and government bonds
  • Smaller tokens and crypto-related stocks also fell, adding to the downward momentum

Bitcoin dropped under $90,000 for the first time since Jan. 9, hitting $88,894 by 9:27 a.m. in Singapore. The move echoed selloffs in stocks, long-term Treasuries, and Japanese bonds amid heightened volatility in debt markets.

The shift is significant because the sell-off hasn’t been confined to a single market. U.S. stocks experienced their sharpest one-day decline in three months on Tuesday. Bitcoin tumbled over 3% as investors dialed back risk appetite following President Donald Trump’s renewed tariff threats linked to his Greenland ambitions.

In crypto circles, $90,000 isn’t just a number. Karim Dandashy, an OTC trader at Flowdesk, called it a “critical” support level that’s held since early January. Meanwhile, ether tumbled more than 7%, Solana dropped 5.3%, Coinbase lost 5.6%, and Strategy plunged nearly 8%, according to The Business Times. The report also noted Strategy snapped up about $2.13 billion in bitcoin over the past eight days, while U.S.-listed bitcoin ETFs have attracted roughly $1.2 billion so far this year. The Business Times

Bitcoin slid to $89,929 Tuesday, then bounced back to $90,535, according to Yahoo Finance. Trading volume climbed 14%.

Bitcoin dipped below $91,000 early in European trading before finding some footing, while ethereum dropped 3.4% to $3,112, according to Barron’s. The decline comes amid rising tensions between the U.S. and Europe.

Long-dated Treasuries—U.S. government bonds with extended maturities—can move sharply when investors quickly reassess inflation, growth, or policy risk. Sudden yield jumps and rising volatility often push money out of riskier assets, and for many funds, crypto remains squarely in that category.

The recent drop has reignited a familiar debate: is bitcoin a hedge, or just another risk asset that tanks when jitters hit? “Bitcoin isn’t quite doing the thing that it’s built to do, at least in real time,” said Alex Thorn, head of research at Galaxy Digital. Meanwhile, Bitunix analyst Dean Chen told Investopedia that bitcoin is “living in a split narrative” between crypto-native buyers and the wider market.

At Davos, SkyBridge Capital’s Anthony Scaramucci called bitcoin’s recent slump “more of a timing issue than a direction issue,” expressing hopes it rebounds to somewhere between $125,000 and $150,000. He flagged the brutal downside volatility, recalling last year’s plunge after bitcoin peaked above $126,000 in October 2025, which wiped out over $19 billion in leveraged positions—traders forced to liquidate when margin calls couldn’t be met. Reuters

The road ahead isn’t straightforward. Should bond-market turmoil worsen and stocks continue to slide, key round-number marks like $90,000 could act as tripwires, forcing leveraged traders to exit and dragging prices down in sharp, brief moves. On the other hand, if yields stabilize and tariff news fades, bitcoin could rebound just as fast — it’s happened before, typically when macro traders ease off the sell pressure simultaneously.

At the moment, bitcoin’s price is reacting more to factors outside the crypto sphere—like government bonds, geopolitical events, and upcoming policy announcements. That’s leaving the market uneasy, and what looked like strong “support” levels just a week ago now seem far less reliable.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Australia stock market today: ASX 200 slips again as banks drag; Rio, gold stocks soften the blow
Previous Story

Australia stock market today: ASX 200 slips again as banks drag; Rio, gold stocks soften the blow

Lululemon pulls new ‘Get Low’ leggings from online store after see-through complaints
Next Story

Lululemon pulls new ‘Get Low’ leggings from online store after see-through complaints

Go toTop